Story
Alternative Asset Managers Fuel US Energy Infrastructure Boom with Insurance Capital

Summary
Firms like Apollo, Blackstone, and KKR are channeling billions from their insurance arms into U.S. LNG and pipeline projects, reshaping how the nation's energy infrastructure is financed.
A new wave of capital from alternative asset managers is powering the expansion of America's energy infrastructure, funding major liquefied natural gas (LNG) export terminals and pipeline networks. Firms including Apollo Global Management, Blackstone, and KKR are deploying cash from their insurance businesses, filling a critical financing need for the energy sector.
A Surge in Private Capital
This influx of investment is driven by heightened global demand for U.S. energy exports, spurred by geopolitical instability, and the growing domestic need for power to support new AI infrastructure. In 2026 alone, alternative investors have participated in transactions in the LNG and midstream sectors valued at $20.35 billion, more than double the total for all of 2024, according to data provider Infralogic.
This type of financing is a strategic fit for both parties. Energy infrastructure projects with long-term contracts offer the stable, lower-risk returns sought by insurance capital. "This is a marriage of assets that have proven over time to be generally lower risk, with capital that wants to invest for the long term in lower-risk assets with steady returns," said Rick Campbell, senior managing director at Blackstone Credit and Insurance, in a statement to Reuters.
Landmark Transactions
Nearly every major LNG project approved since 2025 has involved private capital alongside traditional lenders. This shift reflects a view of LNG facilities as long-lived infrastructure assets rather than purely commodity businesses, with sales agreements often locking in revenue for up to 20 years.
AdRecent major deals include:
- A $9 billion investment from Apollo to back ONEOK, including its acquisition of Midland basin assets.
- A $7 billion investment for the second phase of Sempra Infrastructure’s Port Arthur LNG facility.
- A $5.34 billion Blackstone-led investment to support power projects being developed by pipeline operator Williams.
- A $3.5 billion deal in late 2024 where EQT sold a 49% stake in a midstream joint venture to Blackstone Credit & Insurance.
Evolving Financing Structures
The nature of these investments is also evolving. While many deals fund specific, ring-fenced projects, ONEOK's recent transaction with Apollo broke new ground. The deal created a structure for Apollo to make a minority investment directly in ONEOK’s equity, providing a new model for public companies to raise significant capital without issuing shares on the public market.
"This has the potential to become an additional funding option for public companies, as you can raise equity at scale without having to go to the public markets," said Jeffrey Mensch, head of M&A structuring at Barclays, which advised ONEOK on the transaction, according to Reuters. For project developers, the trend offers a welcome expansion of funding sources. As Daniel Vogel, a partner at Apollo, told Reuters, "There is ample capital out there, so for project developers, it’s about having diversification of sources."
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.